Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting

ATXS 10.30.2024

Full Press ReleaseSEC FilingsOur ATXS Tweets

About Gravity Analytica

Recent News

  • 01.23.2025 - Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
  • 01.13.2025 - Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE
  • 01.03.2025 - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
PDF Version

BOSTON--(BUSINESS WIRE)--Oct. 30, 2024--Astria Therapeutics, Inc.(Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present interim quality of life results from the ALPHA-STAR trial of navenibart (STAR-0215) at the Canadian Society of Allergy and Clinical Immunology (CSACI) AnnualScientific MeetinginBanff, Alberta, CanadaonNovember 7, 2024.

Adil Adatia, M.D., Assistant Professor in theDepartment of Medicineat theUniversity of AlbertainEdmonton, Albertaand Director of theUniversity of Alberta Angioedema Centreof Reference and Excellence (ACARE), will present a poster titled “Quality of life (QoL) improvements in hereditary angioedema (HAE) with STAR-0215; interim results from the phase 1b/2 ALPHA-STAR clinical trial.” The poster will be exhibited in the Van Horne Foyer from10:00am MDTonThursday, November 7until the end of day onSaturday, November 9.

AboutAstria Therapeutics:Astria Therapeuticsis a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website,www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241030578125/en/

Astria:Investor Relations and Media:Elizabeth Higginsinvestors@astriatx.com

Source:Astria Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com